Stories
Slash Boxes
Comments

SoylentNews is people

Submission Preview

Link to Story

Predatory Bacteria As a New 'Living' Antibiotic

Accepted submission by Phoenix666 at 2017-03-21 21:22:08
Science

Antibiotic resistance is one of medicine's most pressing problems. Now, a team from Korea is tackling this in a unique way: using bacteria to fight bacteria [phys.org].

Before the discovery of penicillin in 1928, millions of lives were lost to relatively simple microbial infections. Since then, antibiotics have transformed modern medicine. The World Health Organization estimates that, on average, antibiotics add 20 years to each person's life. However, the overuse of antibiotics has put pressure on bacteria to evolve resistance against these drugs, leading to the emergence of untreatable superbugs.

Now, researchers at South Korea's Ulsan National Institute of Science and Technology (UNIST) aim to fight fire with fire by launching predatory bacteria capable of attacking other bacteria without harming human cells. "Bacteria eating bacteria. How cool is that?" asks Professor Robert Mitchell, the team leader. He and his colleagues are also developing a natural compound called violacein to tackle Staphylococcus, a group of around 30 different bacteria known to cause skin infections, pneumonia and blood poisoning. Some Staphylococcus bacteria such as MRSA (methicillin-resistant Staphylococcus aureus) are resistant to antibiotics, making infections harder to treat.

Violacein is a so-called 'bisindole': a metabolite produced by bacteria from the condensation of two molecules of tryptophan (an essential amino acid used in many organisms to ensure normal functioning and avoid illness and death). This compound is vibrant purple in colour and of interest to researchers for its anticancer, antifungal and antiviral properties. Researchers have discovered that it can stop bacteria from reproducing, and even kill the multidrug resistant bacterium Staphylococcus aureus, when used in the right doses. It also works well in conjunction with other existing antibiotics.


Original Submission